RecruitingNCT05660642

An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression

This recruiting study focuses on depression and currently lists sites or participation links in United Kingdom.

DepressionOtherFrom 18 Years to 75 Years

In plain English

Key information made simple

This study exists to better understand the safety of the medication BPL-003 and how manageable it feels in practice. Researchers are trying to understand whether the medication BPL-003 can give earlier or clearer feedback during care. For people living with Depression, being understood earlier and more clearly can shape the whole care journey. If the findings are useful, they could lead to earlier recognition and more informed decisions later on. Taking part helps build the evidence that can improve understanding and care for others over time.

What to expect

Your next step

The official record suggests in-person participation through a university, with sites including MAC Clinical Research in Liverpool, Hammersmith Medicines Research in London, and King's College London, Clinical Trials Facility in London. Participation appears to involve guided sessions or support activities with check-ins on how they fit into daily life. The main fit is usually matching the main diagnosis, while common reasons not to take part include active substance or alcohol problems that could affect the results and safety concerns that need urgent care first. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record

Interested?

Check my eligibility

Study reference: NCT05660642. Your email is the only field you need to provide here.

In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular follow-up, often through questionnaires or interviews.

Requires travel, with in-person participation in United Kingdom.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com